NCT00491244 - Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C | Biotech Hunter

Enrollment

377

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Chronic Hepatitis C

Interventions

DRUG

Peginterferon alfa-2a and ribavirin

Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)

DRUG

Peginterferon alfa-2a

Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors

collaborator

National Science and Technology Council, Taiwan

OTHER_GOV

collaborator

Department of Health, Executive Yuan, R.O.C. (Taiwan)

OTHER_GOV

lead

National Taiwan University Hospital

OTHER